Neuroguard IEP Embolic Protection System
Contego Medical, Inc. · Decision date Nov 4, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on 11/04/2026 for the Neuroguard IEP Embolic Protection System, submitted by Contego Medical, Inc. of Raleigh, North Carolina, under 510(k) number K260600. The application was received 02/24/2026 and reviewed by the Cardiovascular panel under regulation 870.1250, product code NTE, classified as a temporary carotid catheter for embolic capture. A SESE decision is a 510(k) clearance, not a premarket approval.
The record lists two clinical trials, NCT04201132 and NCT05845710, and states the submission was not reviewed by a third party, was not a combination product, and had no authorized predetermined change control plan. The public page does not describe the specific device components, modifications, or performance data supporting the decision, and no summary or statement is included here. Whether the listed trials informed this clearance, and what they evaluated, remains unstated in the available record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260600
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Contego Medical, Inc.
- Product code
- NTE
- Decision code
- SESE
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Temporary Carotid Catheter For Embolic Capture.
- Applicant
- Contego Medical, Inc.
- Product code
- NTE
- FDA device class
- 2
FDA decision timeline
K260600 received
Application receipt date recorded by FDA.
K260600 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Contego Medical, Inc.
- Headquarters
- Not reported
- Brand website
- contegomedical.com
- FDA applicant address
- Raleigh, NC
Sources and methodology
- Original FDA record: K260600
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records